An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients with Advanced Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs P 7170 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Piramal Enterprises
- 02 Sep 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 03 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Dec 2013 Planned End Date changed from 1 Mar 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov.